The Journal of Critical Limb Ischemia (JCLI) is the official publication of the CLI Global Society. Members have complimentary access to view and download all articles and are encouraged to submit content for this publication. If you’d like to become a member, or learn more about the Society, visit www.cliglobalsociety.org.
This peer-reviewed journal launched in March 2021. It is currently indexed in Scopus.
Journal of Critical Limb Ischemia 70 East Swedesford Road, Suite 100, Malvern, PA 19355. Phone: 1-800-237-7285 Phone: 610-560-0500 Fax: 610-560-0502
ISSN: 2694-3026
Editorial Policies / Publication Ethics and Malpractice
Statements and opinions expressed by authors are their own and not necessarily those of the publisher, editorial staff, or any member of the Editorial Advisory Board. The publisher of the Journal of Critical Limb Ischemia accepts no responsibility for statements made by contributors or claims made by advertisers, nor does the publication of advertisements constitute or imply endorsement. Manuscripts are accepted for publication in the Journal of Critical Limb Ischemia with the understanding that their content, all or in part, has not been published elsewhere and will not be published elsewhere, except in abstract form or by the express consent of the Managing Editor.
Authorship and Contribution
JCLI adheres to the ICMJE guidelines on Authorship and Contribution. Only those with substantial intellectual contributions should be included as an authors. Co-authors will receive an email prompting them to confirm their contributions to the submission. Each author should respond to the email via the appropriate link (“Yes, I am an author” or “No, I am not an author”). Authors may indicate multiple authors who contributed equally. In such cases, authors should include a notation on the title page regarding which authors contributed equally to the work. It is the responsibility of the authors, institutions, or third parties, to determine order of authorship, acknowledgments, and institutional affiliations.
All manuscripts submitted for publication must include the following statement signed by the senior author within the cover letter: “The undersigned author transfers all copyright ownership of the manuscript entitled (title of article) to HMP Global in the event the work is published. The author warrants that the article is original, is not under consideration by another journal, and has not been previously published. I sign for and accept responsibility for releasing this material on behalf of any and all co-authors.”
Authors must comply with FDA guidelines, human studies guidelines and animal welfare regulations of the authors’ institution. Authors should indicate in the paper that human subjects have given informed consent and that the authors have conformed to institutional guidelines and those of the American Physiological Society. By submitting your manuscript to JCLI you agree to a plagiarism screen via iThenticate. All submissions will be screened for plagiarism before being reviewed by the peer-review panel.
Author Processing Fees
There are no fees associated with submission or publication in the Journal of Critical Limb Ischemia.
Conflicts of Interest
The Journal of Critical Limb Ischemia requires authors to disclose possible conflict of interest situations (financial or personal interests), real or apparent, that may affect or appear to affect the impartiality and the integrity of the peer review process. These include employment, financial benefit, and public advocacy. These disclosures do not necessarily exclude an article from consideration for publication; the goal of disclosure is transparency. Reviewers and editors are expected to follow these same standards and to recuse themselves from participating in the review of manuscripts relevant to such interests. For more information, consult the ICMJE financial disclosure policy
Best Practices
Manuscripts must conform to Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations). In addition, the Journal of Critical Limb Ischemia adheres to COPE core practices (scholarly research and publications guidelines) as a guide to the highest standards in publication ethics.
Peer Review Policy
All submissions are peer reviewed by 2 to 3 referees who are experts in the field. The JCLI peer-review process is single-anonymized (single-blind). This is the most common form of peer review among science journals. Acceptance is based upon significance and originality. If an article is accepted for publication, the corresponding author will be notified via e-mail through Editorial Manager and the content revision requirements supplied by the peer reviewers will be included. Additional editorial revisions may be made to articles accepted as an aid to clarity. If an article is not accepted, the corresponding author will be notified by e-mail through Editorial Manager. To avoid significant delays in the peer review or editorial processing of your manuscript, please adhere to the submission guidelines.
Complaints and Appeals
Appeals to editor decisions need to provide strong evidence of new data or information in response to the reviewers’ and/or editor’s comments. The journal follows the Committee on Publication Ethics (COPE) https://publicationethics.org/ guidelines on appeals to editor decisions and complaints about the peer review process. For complaints about the editorial management, please contact the editor and the managing editor.
Confidentiality
Editors and editorial staff will not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.
Misconduct
JCLI editors are dedicated to following best practices on ethical matters, errors, and retractions. Editors will take reasonable steps to identify and prevent publication of papers where research misconduct has occurred. Action taken will be in accordance with COPE https://publicationethics.org/ guidelines. The editorial board does not tolerate plagiarism in any form, including (but are not limited to) affiliation misrepresentation, breaches in copyright, use of third-party material without permissions, citation manipulation, duplicate submission/publication, image or data manipulation/fabrication, peer review manipulation, plagiarism, text-recycling/self-plagiarism, and undisclosed competing interests and/or unethical research.
Post Publication Discussion and Corrections
After an article has been published it may be necessary to make a change to the Version of Record. This will be done after careful consideration by the Editor in accordance with guidance from the Committee on Publication Ethics (COPE). If a change is deemed necessary, it will be published with a statement which will be permanently linked to the original article, such as a Correction notice, an Expression of Concern, a Retraction, or a Removal.
Archival
The Journal of Critical Limb Ischemia content is registered with the CLOCKSS repository for electronic preservation.
Editorial
Jihad A. Mustapha, MD
Editor-in-Chief
Founding Board Member, Treasurer/Secretary, CLI Global Society
Chief Executive Officer, ACV Centers
Associate Clinical Professor of Medicine, Michigan State University College of Human Medicine, Lansing, Michigan
For information regarding journal content or writing for the Journal of Critical Limb Ischemia, please contact:
Cynthia Laufenberg
Managing Editor
HMP Global
claufenberg@hmpglobal.com
Production
Elizabeth Vasil
HMP Global
Layout/Production Manager, 1-800-237-7285, ext. 4239
evasil@hmpglobal.com
Business Staff
For information regarding advertising in the Journal of Critical Limb Ischemia, contact one of the following:
Joshua D. Hartman, Senior Vice President, Cardiovascular & Public Safety Divisions
Tel: (302) 786-6231, email jhartman@hmpglobal.com
Colleen Waters, Associate Vice President, US Cardiovascular Division
Tel: (609) 630-6203, email cwaters@hmpglobal.com
Carson McGarrity, Director, National Accounts, US Cardiovascular Division
Tel: (215) 262-4739, email cmcgarrity@hmpglobal.com
Stephanie Starman, Senior Manager, National Accounts, US Cardiovascular Division
Tel: (800) 237-7285, ext. 4118, email sstarman@hmpglobal.com
Elizabeth A. McKee, Sales Operations Manager, US Cardiovascular Division
Tel: (800) 237-7285, x4266, email emckee@hmpglobal.com
Advertising Policy
Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of HMP Global, the editorial staff, or any member of the editorial advisory board. HMP Global is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this journal is not a warranty, endorsement or approval of the products or services advertised or of their effectiveness, quality or safety. Rapid advances in medicine may cause information contained here to become outdated, invalid or subject to debate. Accuracy cannot be guaranteed. HMP Global disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.
For classified advertising, visit www.healthjobconnect.com for more information.
For more information, please visit our online sales portal.
HMP Omnimedia
70 E. Swedesford Rd., Ste. 100
Malvern, PA 19355 USA